Abstract
The androgen receptor (AR) has a crucial role in prostate cancer. RNA‑binding protein‑mediated post‑transcriptional regulation is important in the initiation and development of cancer. The present study attempted to elucidate the mutual association of AR and RNA‑binding protein quaking (QKI) in the development of prostate cancer. Dual‑luciferase reporter demonstrated that AR can positively regulate the expression of QKI in prostate cancer cell lines due to its effective transcription regulating function. In addition, QKI may increase expression of AR by heat shock protein 90, which is a coactivator of AR, and silencing QKI can increase the sensitive of Casodex, which is an antagonist of AR in castration‑resistant prostate cancer. This may be a new strategy for advanced prostate cancer.
MeSH terms
-
Aged
-
Androgen Receptor Antagonists / pharmacology
-
Androgen Receptor Antagonists / therapeutic use
-
Anilides / pharmacology
-
Anilides / therapeutic use
-
Apoptosis / genetics
-
Cell Cycle / drug effects
-
Cell Cycle / genetics
-
Cell Line, Tumor
-
Cell Proliferation
-
Gene Expression Regulation, Neoplastic*
-
Gene Silencing
-
Humans
-
Male
-
Middle Aged
-
Nitriles / pharmacology
-
Nitriles / therapeutic use
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / genetics*
-
Prostatic Neoplasms / metabolism*
-
Prostatic Neoplasms / pathology
-
RNA, Small Interfering / genetics
-
RNA-Binding Proteins / genetics*
-
Receptors, Androgen / metabolism*
-
Tosyl Compounds / pharmacology
-
Tosyl Compounds / therapeutic use
Substances
-
AR protein, human
-
Androgen Receptor Antagonists
-
Anilides
-
Nitriles
-
QKI protein, human
-
RNA, Small Interfering
-
RNA-Binding Proteins
-
Receptors, Androgen
-
Tosyl Compounds
-
bicalutamide